Julia Owens: A Deep Dive Into Stroke Care and Basking Bio’s Innovative Programs
Julia Owens, Chief Executive Officer at Basking Biosciences Inc, reposted from Basking Biosciences, Inc. on LinkedIn:
”I have long admired Josh Schimmer‘s biotech insights and wit, so I was thrilled when he wanted to learn more about our work at Basking Bio.
I hope you will listen to this webinar where Josh and Alexa dig into the background of stroke care and our innovative programs with their usual probing questions.”
Quoting Basking Biosciences, Inc.‘s post:
”We had the privilege of joining Josh Schimmer and Alexa Deemer Conzola at Cantor Fitzgerald for a deep dive into acute ischemic stroke and the science behind our lead program, BB-031.
In the recording below, our CEO, Julia Owens, and Co-founder and Chief Scientific Officer, Dr. Shahid Nimjee, walk through the stroke treatment landscape, why targeting von Willebrand Factor represents a fundamentally different approach, and where BB-031 stands in its clinical development.
Thank you, Josh and the Cantor team, for the opportunity to share our story with your audience.
Stay updated with Hemostasis Today.
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning
-
Nov 14, 2026, 23:33Mona Alfaraj: International Pathology Day Promotes Education in Hemoglobinopathy Diagnostics
-
Nov 14, 2026, 23:33Alexandros Makis: Exploring Vascular Mechanisms and Therapeutic Targets in β-Thalassemia
-
Nov 14, 2026, 23:32Kalyan Roy: Asundexian Approval Marks a Milestone in Targeted Anticoagulation
-
Nov 14, 2026, 23:32Julia Pitcher: Strengthening Legislative Efforts for the Sickle Cell and Thalassemia Community